Possible link between rotavirus vaccine and decline in type 1 diabetes

A drop in the number of young children diagnosed with type 1 diabetes could be associated with the introduction of routine rotavirus vaccination of …

Less Than Half with Type 1 Diabetes in the U.S. Achieve Treatment Goals

A new study has shown that only a minority of patients in the U.S. with type 1 diabetes achieve target levels of hemoglobin A1c, a measure of blood …

First Human Trial of Stem Cell-derived Implants Underway in Type 1 Diabetes in Europe

The Center for Beta Cell Therapy in Diabetes and ViaCyte, Inc., announced that a human stem cell-derived product candidate has been implanted in …

Managing Diabetes and Close Relationships

By Jen Nash, DClinPsych With Valentine’s Day approaching, your thoughts may be turning to your nearest and dearest. Have you considered how …

FDA Advisory Committee Votes 50/50 on Approving New Type 1 Diabetes Drug

An advisory committee of the Food and Drug Administration (FDA) voted in a tie yesterday on the approval of a novel type 1 diabetes drug which would …

New Risk Score Far More Effective for Diabetes Diagnosis

A new way of screening babies and adults for future risk of type 1 diabetes will be much more effective at identifying the condition than current …

Study: Following AHA’s Life’s Simple 7® May Reduce Diabetes Risk Significantly

It’s known that heart disease and diabetes often go hand in hand. Now, new research proves that following the American Heart Association’s …

Medical Detection Dogs Help Diabetes Patients Regulate Insulin Levels

New research from the U.K. finds that well-trained alert dogs have the potential to vastly improve the quality of life of people living with type 1 …

Bigfoot Biomedical Partners Up with Lilly for Insulin Delivery System

Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, …

ViaCyte Updates on Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes

ViaCyte, Inc., a regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments,  announced …